Carbios significantly reduced its operating expenses during 2025, resulting in a €7 million reduction in operating loss Carbios has a solid cash position of €59 million as of December 31, 2025, on a Group basis including subsidiaries1, enabling it to cover its operating expenses beyond the next 12 months. Projected cash consumption for 2026, excluding the Longlaville project, is estimated at €20 million The 4 strategic priorities for 2026 are:Resume the Longlaville industrial project, subject to the completion of its financing, with closing expected by Q3 20262 Deploy Carbios’ PET biorecycling technology in Asia through the construction of a first facility operated under a license agreement with Wankai Accelerate the commercial development to secure new license agreements across Europe, North America and South America Maintain a strict...

Quarterly direct result per share (DRPS) € 0.45, +2% compared with prior year period Occupancy shopping centers 97.5%, up 1.0 percentage point (pp) compared with Q1 2025 Quarterly Full Service Center footfall +2.0% compared with prior year period € 12m in strategic acquisitions closed, funded through issuance of new shares, resulting in a 0.2 pp improvement in loan-to-value Refinancing of € 250m revolving credit facility (RCF) completed, at improved terms, with a tenor of five years plus extension options up to seven years Despite ongoing geopolitical tensions, we remain confident in our 2026 DRPS forecast of € 1.85-1.95AttachmentWereldhave_Trading-update-Q1-2026

NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the pricing of its previously announced underwritten public offering of 11,600,000 shares of its common stock at a public offering price of $13.00 per share, for total proceeds of approximately $150 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. All of the shares in the offering are being sold by Trevi. In addition, Trevi has granted the underwriters a 30-day option to purchase up to 1,740,000 additional...

Enters into Cooperation Agreement with Altai Capital Board to Seek Shareholder Approval for Declassification at the 2026 Annual Meeting BETHLEHEM, Pa., April 16, 2026 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of John D. Bertrand to its Board of Directors as an independent director, effective immediately. Mr. Bertrand is a healthcare technology executive with more than a decade of experience driving AI-enabled innovation in diagnostics. He co-founded Digital Diagnostics Inc. and most recently served as its Chief Executive Officer, helping to transform the company from a research-stage organization into a global commercial platform for disease diagnosis. Previously, Mr. Bertrand...

PERTH, Australia, April 16, 2026 (GLOBE NEWSWIRE) — Paladin Energy Ltd (ASX:PDN, TSX:PDN, OTCQX:PALAF) (“Paladin” or the “Company”) provides an operations and guidance update for the Langer Heinrich Mine (LHM) in advance of its March 2026 Quarterly Report, which is scheduled for release on 22 April 2026. The LHM ramp-up and transition to full mining operations has progressed well during the first nine months of FY2026. The combination of successful mobilisation of the mining fleet, improved feed grade and high recovery rates from the processing plant have resulted in year-to-date FY2026 production of 3.6Mlb U3O8. As a result of the strong performance in the first nine months of FY2026, Paladin has revised its FY2026 guidance as follows:LHM FY2026 Guidance Update (100%1)   FY20262 Revised GuidanceU3O8 Produced Mlb 4.0 – 4.4 4.5...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION TO THE UNITED STATES BROOKFIELD, NEWS, April 16, 2026 (GLOBE NEWSWIRE) — Brookfield Corporation (NYSE: BN, TSX: BN) today announced the pricing of a public offering of C$500 million aggregate principal amount of medium-term notes due April 21, 2036 (the “2036 notes”), which will bear interest at a rate of 4.803% per annum, payable semi-annually, and the pricing of a C$250 million re-opening of its 5.399% medium term notes due December 11, 2055 (the “2055 notes” and together with the 2036 notes, the “notes”). The 2055 notes will form part of the same series as the already outstanding C$650 million aggregate principal amount of 5.399% notes due December 11, 2055 (the “existing notes”), which were issued on December 11, 2025. After giving effect to the re-opening,...

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) — Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the pricing of its initial public offering of 39,062,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares of common stock are being offered by Kailera. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Kailera, are expected to be $625.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. Kailera’s common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “KLRA” on April 17, 2026. The offering is expected to close on...

Picard to showcase the SynCardia TAH and next-generation innovation TUCSON, Ariz., April 16, 2026 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC, (“SynCardia”) maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced its participation in the International Society for Heart and Lung Transplantation (“ISHLT”) 2026 Annual Meeting, to be held at the Metro Toronto Convention Centre in Toronto, Canada. The ISHLT Annual Meeting is a leading global forum for clinicians, researchers and industry participants focused on the treatment of advanced heart and lung failure, featuring the latest clinical data, emerging technologies and advances in transplantation and mechanical circulatory support. Andre...

MARKHAM, Ontario, April 16, 2026 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today announced the results of matters voted on at its annual meeting of shareholders held on April 16, 2026 (the “Meeting”). The voting results for each of the matters considered at the Meeting are presented below. The total number of common shares represented by shareholders present in person or by proxy at the Meeting was 55,459,399, representing 58.71% of the Company’s outstanding common shares. 1.   Election of Directors On a vote by ballot, the election of the following nine nominees as directors of the Company to hold office until the next annual meeting of the Company, or until their respective successors are elected or appointed, was approved. The results of the vote on this matter are set out below.Nominee Votes...